Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 396

1.

The Binding of Human IgG to Minipig FcγRs - Implications for Preclinical Assessment of Therapeutic Antibodies.

Egli J, Schlothauer T, Spick C, Seeber S, Singer T, Odermatt A, Iglesias A.

Pharm Res. 2019 Feb 5;36(3):47. doi: 10.1007/s11095-019-2574-y.

2.

Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.

Scheuer W, Thomas M, Hanke P, Sam J, Osl F, Weininger D, Baehner M, Seeber S, Kettenberger H, Schanzer J, Brinkmann U, Weidner KM, Regula J, Klein C.

MAbs. 2016;8(3):562-73. doi: 10.1080/19420862.2016.1147640.

3.

TriFabs--Trivalent IgG-Shaped Bispecific Antibody Derivatives: Design, Generation, Characterization and Application for Targeted Payload Delivery.

Mayer K, Baumann AL, Grote M, Seeber S, Kettenberger H, Breuer S, Killian T, Schäfer W, Brinkmann U.

Int J Mol Sci. 2015 Nov 17;16(11):27497-507. doi: 10.3390/ijms161126037.

4.

Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody.

Fischer JA, Hueber AJ, Wilson S, Galm M, Baum W, Kitson C, Auer J, Lorenz SH, Moelleken J, Bader M, Tissot AC, Tan SL, Seeber S, Schett G.

Arthritis Rheumatol. 2015 Jan;67(1):51-62. doi: 10.1002/art.38896.

5.

A robust high throughput platform to generate functional recombinant monoclonal antibodies using rabbit B cells from peripheral blood.

Seeber S, Ros F, Thorey I, Tiefenthaler G, Kaluza K, Lifke V, Fischer JA, Klostermann S, Endl J, Kopetzki E, Pashine A, Siewe B, Kaluza B, Platzer J, Offner S.

PLoS One. 2014 Feb 4;9(2):e86184. doi: 10.1371/journal.pone.0086184. eCollection 2014.

6.

10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL).

Eberhardt WE, Gauler TC, Lepechoux C, Stamatis G, Bildat S, Krbek T, Welter S, Grunenwald D, Fischer B, Rodrigo Hde L, Theegarten D, Le Chevalier T, Seeber S, Stuschke M, Poettgen C.

Lung Cancer. 2013 Oct;82(1):83-9. doi: 10.1016/j.lungcan.2013.06.007. Epub 2013 Aug 16.

PMID:
23957964
7.

Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies.

Schlothauer T, Rueger P, Stracke JO, Hertenberger H, Fingas F, Kling L, Emrich T, Drabner G, Seeber S, Auer J, Koch S, Papadimitriou A.

MAbs. 2013 Jul-Aug;5(4):576-86. doi: 10.4161/mabs.24981. Epub 2013 May 29.

8.

A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.

Thomas M, Kienast Y, Scheuer W, Bähner M, Kaluza K, Gassner C, Herting F, Brinkmann U, Seeber S, Kavlie A, Welschof M, Ries S, Weidner KM, Regula JT, Klein C.

PLoS One. 2013;8(2):e54923. doi: 10.1371/journal.pone.0054923. Epub 2013 Feb 6.

9.

TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNFα, from CD3+CD161+ T cells to exacerbate gut inflammation.

Jin S, Chin J, Seeber S, Niewoehner J, Weiser B, Beaucamp N, Woods J, Murphy C, Fanning A, Shanahan F, Nally K, Kajekar R, Salas A, Planell N, Lozano J, Panes J, Parmar H, DeMartino J, Narula S, Thomas-Karyat DA.

Mucosal Immunol. 2013 Sep;6(5):886-99. doi: 10.1038/mi.2012.124. Epub 2012 Dec 19.

PMID:
23250276
10.

Solid-phase synthesis of sequence-defined T-, i-, and U-shape polymers for pDNA and siRNA delivery.

Schaffert D, Troiber C, Salcher EE, Fröhlich T, Martin I, Badgujar N, Dohmen C, Edinger D, Kläger R, Maiwald G, Farkasova K, Seeber S, Jahn-Hofmann K, Hadwiger P, Wagner E.

Angew Chem Int Ed Engl. 2011 Sep 12;50(38):8986-9. doi: 10.1002/anie.201102165. Epub 2011 Aug 11. No abstract available.

PMID:
21837712
11.

Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells.

Block M, Fister S, Emons G, Seeber S, Gründker C, Günthert AR.

Anticancer Res. 2010 Jun;30(6):2025-31.

PMID:
20651347
12.

Mapping of disulfide bonds within the amino-terminal extracellular domain of the inhibitory glycine receptor.

Vogel N, Kluck CJ, Melzer N, Schwarzinger S, Breitinger U, Seeber S, Becker CM.

J Biol Chem. 2009 Dec 25;284(52):36128-36. doi: 10.1074/jbc.M109.043448. Epub 2009 Oct 27.

13.

High-level production of a humanized immunoRNase fusion protein from stably transfected myeloma cells.

Krauss J, Exner E, Mavratzas A, Seeber S, Arndt MA.

Methods Mol Biol. 2009;525:471-90, xiv. doi: 10.1007/978-1-59745-554-1_24.

PMID:
19252845
14.

Drug resistance and DNA repair in leukaemia.

Müller MR, Thomale J, Rajewsky MF, Seeber S.

Cytotechnology. 1998 Sep;27(1-3):175-85. doi: 10.1023/A:1008064804678.

15.

Long-term survival in patients with inoperable and metastasized cancer.

Seeber S.

Onkologie. 2008 Sep;31(8-9):427-8. doi: 10.1159/000143109. Epub 2008 Jul 3. No abstract available.

16.

Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma.

Schütt P, Zimmermann K, Derks C, Ebeling P, Welt A, Poser M, Hense J, Metz K, Anhuf J, Sandmann M, Neise M, Moritz T, Stuschke M, Niederle N, Seeber S, Nowrousian MR.

J Cancer Res Clin Oncol. 2009 Mar;135(3):459-66. doi: 10.1007/s00432-008-0467-2. Epub 2008 Aug 29.

PMID:
18758815
17.

The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients.

Schütt P, Rebmann V, Brandhorst D, Wiefelspütz J, Ebeling P, Opalka B, Seeber S, Nowrousian MR, Moritz T, Grosse-Wilde H.

Hum Immunol. 2008 Feb;69(2):79-87. doi: 10.1016/j.humimm.2008.01.006. Epub 2008 Feb 7.

PMID:
18361931
18.

Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.

Ebeling P, Eisele L, Schuett P, Bauer S, Schuette J, Moritz T, Seeber S, Flasshove M.

Onkologie. 2008 Feb;31(1-2):11-6. doi: 10.1159/0000111756. Epub 2008 Jan 22.

PMID:
18268394
19.

Dependency of intraocular pressure elevation and glaucomatous changes in DBA/2J and DBA/2J-Rj mice.

Scholz M, Buder T, Seeber S, Adamek E, Becker CM, Lütjen-Drecoll E.

Invest Ophthalmol Vis Sci. 2008 Feb;49(2):613-21. doi: 10.1167/iovs.07-0745.

PMID:
18235006
20.

In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation.

Seshasayee D, Lee WP, Zhou M, Shu J, Suto E, Zhang J, Diehl L, Austin CD, Meng YG, Tan M, Bullens SL, Seeber S, Fuentes ME, Labrijn AF, Graus YM, Miller LA, Schelegle ES, Hyde DM, Wu LC, Hymowitz SG, Martin F.

J Clin Invest. 2007 Dec;117(12):3868-78.

21.

Long-term results of a phase-I/II study of sequential high-dose chemotherapy with autologous stem cell transplantation in the initial treatment of aggressive non-Hodgkin's lymphoma.

Welt A, Schütt P, Derks C, Ebeling P, Müller S, Metz K, Anhuf J, Moritz T, Seeber S, Nowrousian MR.

Tumori. 2007 Sep-Oct;93(5):409-16.

PMID:
18038870
22.

A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease.

Dürig J, Ebeling P, Grabellus F, Sorg UR, Möllmann M, Schütt P, Göthert J, Sellmann L, Seeber S, Flasshove M, Dührsen U, Moritz T.

Cancer Res. 2007 Sep 15;67(18):8653-61.

23.

Myelin proteolipid protein (PLP) as a marker antigen of central nervous system contaminations for routine food control.

Villmann C, Sandmeier B, Seeber S, Hannappel E, Pischetsrieder M, Becker CM.

J Agric Food Chem. 2007 Aug 22;55(17):7114-23. Epub 2007 Jul 13.

PMID:
17629299
24.

Site-specific formation of Maillard, oxidation, and condensation products from whey proteins during reaction with lactose.

Meltretter J, Seeber S, Humeny A, Becker CM, Pischetsrieder M.

J Agric Food Chem. 2007 Jul 25;55(15):6096-103. Epub 2007 Jun 23.

PMID:
17590008
25.
26.

Breast cancer patients' expectations in respect of the physician-patient relationship and treatment management results of a survey of 617 patients.

Oskay-Ozcelik G, Lehmacher W, Könsgen D, Christ H, Kaufmann M, Lichtenegger W, Bamberg M, Wallwiener D, Overkamp F, Diedrich K, von Minckwitz G, Höffken K, Seeber S, Mirz R, Sehouli J.

Ann Oncol. 2007 Mar;18(3):479-84. Epub 2007 Feb 1.

PMID:
17272832
27.

Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia.

Eisele L, Klein-Hitpass L, Chatzimanolis N, Opalka B, Boes T, Seeber S, Moritz T, Flasshove M.

Acta Haematol. 2007;117(1):8-15. Epub 2006 Nov 8.

PMID:
17095854
28.

Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells.

Ebeling P, Bach P, Sorg U, Schneider A, Trarbach T, Dilloo D, Hanenberg H, Niesert S, Seeber S, Moritz T, Flasshove M.

J Cancer Res Clin Oncol. 2007 Mar;133(3):199-209. Epub 2006 Oct 20.

PMID:
17053889
29.

Tax1-binding protein 1 is expressed in the retina and interacts with the GABA(C) receptor rho1 subunit.

Ulrich M, Seeber S, Becker CM, Enz R.

Biochem J. 2007 Jan 15;401(2):429-36.

30.

Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections.

Schütt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, Müller S, Buttkereit U, Opalka B, Lindemann M, Grosse-Wilde H, Seeber S, Moritz T, Nowrousian MR.

Leuk Lymphoma. 2006 Aug;47(8):1570-82.

PMID:
16966269
31.

Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model.

Rattmann I, Kleff V, Sorg UR, Bardenheuer W, Brueckner A, Hilger RA, Opalka B, Seeber S, Flasshove M, Moritz T.

Blood. 2006 Nov 1;108(9):2965-71. Epub 2006 Jul 11.

PMID:
16835384
32.

[Metastases with CUP syndrome].

Seeber S, Strumberg D.

Urologe A. 2006 May;45(5):614-9. Review. German.

PMID:
16710679
33.

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M, von Minckwitz G.

J Clin Oncol. 2006 Apr 20;24(12):1940-9. Erratum in: J Clin Oncol. 2006 Jul 1;24(19):3221.

PMID:
16622270
34.

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.

Richly H, Henning BF, Kupsch P, Passarge K, Grubert M, Hilger RA, Christensen O, Brendel E, Schwartz B, Ludwig M, Flashar C, Voigtmann R, Scheulen ME, Seeber S, Strumberg D.

Ann Oncol. 2006 May;17(5):866-73. Epub 2006 Feb 24.

PMID:
16500908
35.

Response of pseudomyxoma peritonei to gemcitabine.

Eisele L, Sheu SY, Müller-Beissenhirtz H, Welt A, Seeber S.

Acta Oncol. 2006;45(1):98-100. No abstract available.

PMID:
16464804
36.

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, Hofstra E, Voliotis D, Christensen O, Brueckner A, Schwartz B.

Eur J Cancer. 2006 Mar;42(4):548-56. Epub 2006 Jan 19.

PMID:
16426838
37.

Tumor cell dissemination in colon cancer does not predict extrahepatic recurrence in patients undergoing surgery for hepatic metastases.

Schoppmeyer K, Frühauf N, Oldhafer K, Seeber S, Kasimir-Bauer S.

Oncol Rep. 2006 Feb;15(2):449-54.

PMID:
16391868
38.

Generation of multiple stable dermcidin-derived antimicrobial peptides in sweat of different body sites.

Rieg S, Seeber S, Steffen H, Humeny A, Kalbacher H, Stevanovic S, Kimura A, Garbe C, Schittek B.

J Invest Dermatol. 2006 Feb;126(2):354-65.

39.

Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil.

Hilger RA, Richly H, Grubert M, Oberhoff C, Strumberg D, Scheulen ME, Seeber S.

Int J Clin Pharmacol Ther. 2005 Dec;43(12):588-9. No abstract available.

PMID:
16372528
40.

A new oxygen-enriched solution enables human tumor tissue transport without cell devitalization.

Heim M, Hilger RA, Ruebben H, Scharifi M, Kredtke S, Thyssen D, Bach F, Seeber S.

Int J Clin Pharmacol Ther. 2005 Dec;43(12):586-7. No abstract available.

PMID:
16372527
41.

Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.

Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, Poser M, Mueller S, Ebeling P, Welt A, Bradwell AR, Buttkereit U, Opalka B, Flasshove M, Moritz T, Seeber S.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8706-14.

42.

Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells.

Bardenheuer W, Lehmberg K, Rattmann I, Brueckner A, Schneider A, Sorg UR, Seeber S, Moritz T, Flasshove M.

Leukemia. 2005 Dec;19(12):2281-8.

PMID:
16304576
43.

Risk factors for venous thromboembolic events in cancer patients.

Kröger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C, Urbanski K, Seeber S, Scheulen ME.

Ann Oncol. 2006 Feb;17(2):297-303. Epub 2005 Nov 9.

PMID:
16282243
44.

Phase III trials in oncology: setting standards of care?

Seeber S, Braun AH.

Nat Clin Pract Oncol. 2005 Sep;2(9):426-7. No abstract available.

PMID:
16264993
45.

The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.

Braun AH, Stark K, Dirsch O, Hilger RA, Seeber S, Vanhoefer U.

Anticancer Drugs. 2005 Nov;16(10):1099-108.

PMID:
16222152
46.

Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.

Kupsch P, Henning BF, Passarge K, Richly H, Wiesemann K, Hilger RA, Scheulen ME, Christensen O, Brendel E, Schwartz B, Hofstra E, Voigtmann R, Seeber S, Strumberg D.

Clin Colorectal Cancer. 2005 Sep;5(3):188-96.

PMID:
16197622
47.

Validation of protein kinase CK2 as oncological target.

Seeber S, Issinger OG, Holm T, Kristensen LP, Guerra B.

Apoptosis. 2005 Aug;10(4):875-85.

PMID:
16133877
48.

[Surveillance in women with early breast cancer, systematic versus symptom guided follow-up].

Welt A, Seeber S.

Zentralbl Gynakol. 2005 Aug;127(4):213-6. Review. German.

PMID:
16037901
49.

Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo.

Rieg S, Steffen H, Seeber S, Humeny A, Kalbacher H, Dietz K, Garbe C, Schittek B.

J Immunol. 2005 Jun 15;174(12):8003-10.

50.

Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.

Bauer S, Hartmann JT, de Wit M, Lang H, Grabellus F, Antoch G, Niebel W, Erhard J, Ebeling P, Zeth M, Taeger G, Seeber S, Flasshove M, Schütte J.

Int J Cancer. 2005 Nov 1;117(2):316-25.

Supplemental Content

Loading ...
Support Center